Open-mkt buys · 90d
$321.9K
18 trades · 2 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$321.9K
Insiders on file
22
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner | 16 | $205.4K | $0 | 2026-10-23 |
| Schneeberger Daniel | 10% Owner | 6 | $839.7K | $0 | 2026-09-16 |
| Vivo Opportunity Cayman Fund, L.P. | 10% Owner | 6 | $31.8K | $0 | 2026-07-16 |
| Vivo Opportunity, LLC | 10% Owner | 24 | $401.7K | $0 | 2026-07-02 |
| Bathery John Steven | Director | 1 | $0 | $0 | 2025-12-19 |
| Jagpal Netta | Chief Financial Officer | 2 | $0 | $0 | 2025-12-19 |
| Lemerond Nicole | Director | 5 | $0 | $0 | 2025-12-19 |
| Johnson Shane Aaron | Sr. VP & General Manager | 9 | $28.3K | $0 | 2025-12-19 |
| HULL ANDREW | Director | 11 | $14.6K | $0 | 2025-12-19 |
| WOUDENBERG MICHAEL | VP, Chem/Manufacturing/Control | 12 | $0 | $0 | 2025-12-19 |
| ADAMS ERIC A | President & CEO | 20 | $70.0K | $0 | 2025-12-19 |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | 14 | $0 | $0 | 2025-12-19 |
| Klompas Neil A | Director | 2 | $0 | $0 | 2025-12-19 |
| Baldasare Bryan T | Director | 4 | $0 | $0 | 2024-12-20 |
| Grove Janet P | Director | 4 | $0 | $0 | 2024-12-20 |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | 14 | $0 | $43 | 2024-07-31 |
| Tegge Jonathan | Interim CFO | 2 | $0 | $0 | 2023-12-23 |
| Li Sarah | VP Accounting & Controller | 1 | $0 | $0 | 2022-12-16 |
| COLWILL BRUCE | CFO | 4 | $14.3K | $0 | 2022-01-24 |
| Cutler Adam D. | Director | 5 | $0 | $0 | 2022-01-24 |
| Garner William J | Director | 3 | $0 | $0 | 2022-01-24 |
| Sazdanoff Catherine | Director | 3 | $0 | $0 | 2021-12-29 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-23 | 2026-10-27 | 4 | $1.32 | $5 | 956,584 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-19 | 2026-10-20 | 1,086 | $1.32 | $1.4K | 956,580 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-16 | 2026-10-20 | 1 | $1.32 | $1 | 955,494 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-15 | 2026-10-15 | 984 | $1.32 | $1.3K | 955,493 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-14 | 2026-10-15 | 8,021 | $1.33 | $10.7K | 954,509 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-13 | 2026-10-15 | 564 | $1.33 | $750 | 946,488 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-08 | 2026-10-08 | 2,256 | $1.33 | $3.0K | 945,924 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-07 | 2026-10-08 | 3,046 | $1.33 | $4.1K | 943,668 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-06 | 2026-10-08 | 5,601 | $1.33 | $7.4K | 940,622 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-05 | 2026-10-05 | 18,182 | $1.33 | $24.2K | 935,021 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-02 | 2026-10-05 | 8,307 | $1.33 | $11.0K | 916,839 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-10-01 | 2026-10-05 | 16,431 | $1.33 | $21.8K | 908,532 | SEC↗ |
| Schneeberger Daniel | 10% Owner | P Buy | 2026-09-16 | 2026-09-16 | 8,340 | $1.29 | $10.8K | 892,101 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-09-16 | 2026-09-16 | 8,340 | $1.29 | $10.8K | 892,101 | SEC↗ |
| Schneeberger Daniel | 10% Owner | P Buy | 2026-09-15 | 2026-09-16 | 54,256 | $1.30 | $70.5K | 883,761 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-09-15 | 2026-09-16 | 54,256 | $1.30 | $70.4K | 883,761 | SEC↗ |
| Schneeberger Daniel | 10% Owner | P Buy | 2026-09-14 | 2026-09-16 | 28,505 | $1.29 | $36.8K | 829,505 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-09-14 | 2026-09-16 | 28,505 | $1.29 | $36.9K | 829,505 | SEC↗ |
| Vivo Opportunity Cayman Fund, | 10% Owner | P Buy | 2026-07-16 | 2026-07-16 | 19 | $1.55 | $29 | 743,057 | SEC↗ |
| Vivo Opportunity Cayman Fund, | 10% Owner | P Buy | 2026-07-16 | 2026-07-16 | 2 | $1.55 | $3 | 75,019 | SEC↗ |
| Vivo Opportunity Cayman Fund, | 10% Owner | P Buy | 2026-07-15 | 2026-07-16 | 13,761 | $1.55 | $21.3K | 743,038 | SEC↗ |
| Vivo Opportunity Cayman Fund, | 10% Owner | P Buy | 2026-07-15 | 2026-07-16 | 1,389 | $1.55 | $2.2K | 75,017 | SEC↗ |
| ADAR1 Capital Management, LLC | 10% Owner | P Buy | 2026-07-15 | 2026-07-17 | 1,000 | $1.56 | $1.6K | 801,000 | SEC↗ |
| Vivo Opportunity Cayman Fund, | 10% Owner | P Buy | 2026-07-14 | 2026-07-16 | 4,882 | $1.55 | $7.6K | 729,277 | SEC↗ |
| Vivo Opportunity Cayman Fund, | 10% Owner | P Buy | 2026-07-14 | 2026-07-16 | 493 | $1.55 | $764 | 73,628 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-07-02 | 2026-07-02 | 1,460 | $1.55 | $2.3K | 724,395 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-07-02 | 2026-07-02 | 147 | $1.55 | $228 | 73,135 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-07-01 | 2026-07-02 | 3,946 | $1.55 | $6.1K | 722,935 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-07-01 | 2026-07-02 | 398 | $1.55 | $617 | 72,988 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-30 | 2026-07-02 | 55 | $1.54 | $85 | 72,590 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-30 | 2026-07-02 | 545 | $1.54 | $839 | 718,989 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-08 | 2026-06-10 | 29,518 | $1.52 | $44.9K | 718,444 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-08 | 2026-06-10 | 2,982 | $1.52 | $4.5K | 72,535 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-05 | 2026-06-10 | 5,045 | $1.57 | $7.9K | 69,553 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-05 | 2026-06-10 | 49,966 | $1.57 | $78.4K | 688,926 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-04 | 2026-06-10 | 618 | $1.57 | $970 | 64,508 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-04 | 2026-06-10 | 6,125 | $1.57 | $9.6K | 638,960 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-03 | 2026-06-10 | 714 | $1.55 | $1.1K | 63,890 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-03 | 2026-06-10 | 7,069 | $1.55 | $11.0K | 632,835 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-02 | 2026-06-10 | 2,095 | $1.52 | $3.2K | 63,176 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-02 | 2026-06-10 | 20,753 | $1.52 | $31.5K | 625,766 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-01 | 2026-06-10 | 1,498 | $1.55 | $2.3K | 61,081 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-06-01 | 2026-06-10 | 14,838 | $1.55 | $23.0K | 605,013 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-05-29 | 2026-06-10 | 1,632 | $1.57 | $2.6K | 59,583 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-05-29 | 2026-06-10 | 16,164 | $1.57 | $25.4K | 590,175 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-05-21 | 2026-06-10 | 3,118 | $1.69 | $5.3K | 57,951 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-05-21 | 2026-06-10 | 30,882 | $1.69 | $52.2K | 574,011 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-05-20 | 2026-06-10 | 5,154 | $1.56 | $8.0K | 54,833 | SEC↗ |
| Vivo Opportunity, LLC | 10% Owner | P Buy | 2026-05-20 | 2026-06-10 | 51,056 | $1.56 | $79.6K | 543,129 | SEC↗ |
| Schneeberger Daniel | 10% Owner | P Buy | 2026-05-19 | 2026-05-21 | 200,000 | $1.50 | $300.0K | 800,000 | SEC↗ |
| Schneeberger Daniel | 10% Owner | P Buy | 2026-05-19 | 2026-05-21 | 200,000 | $1.56 | $312.0K | 600,000 | SEC↗ |
| Schneeberger Daniel | 10% Owner | P Buy | 2026-05-19 | 2026-05-21 | 68,551 | $1.60 | $109.7K | 400,000 | SEC↗ |
| HULL ANDREW | Director | A Award deriv | 2025-12-19 | 2025-12-19 | 1,750 | — | $0 | 2,711 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2025-12-19 | 2025-12-19 | 35,000 | — | $0 | 49,050 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2025-12-19 | 2025-12-19 | 13,000 | — | $0 | 18,280 | SEC↗ |
| Bathery John Steven | Director | A Award deriv | 2025-12-19 | 2025-12-19 | 1,750 | — | $0 | 5,250 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | A Award deriv | 2025-12-19 | 2025-12-19 | 18,000 | — | $0 | 25,445 | SEC↗ |
| Jagpal Netta | Chief Financial Officer | A Award deriv | 2025-12-19 | 2025-12-19 | 18,000 | — | $0 | 24,250 | SEC↗ |
| Klompas Neil A | Director | A Award deriv | 2025-12-19 | 2025-12-19 | 1,750 | — | $0 | 5,250 | SEC↗ |
| Lemerond Nicole | Director | A Award deriv | 2025-12-19 | 2025-12-19 | 1,750 | — | $0 | 2,725 | SEC↗ |
| Johnson Shane Aaron | Sr VP & General Manager | A Award deriv | 2025-12-19 | 2025-12-19 | 8,500 | — | $0 | 12,400 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | H Expire deriv | 2025-12-15 | 2025-12-17 | 70 | — | $0 | 5,280 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | H Expire deriv | 2025-12-15 | 2025-12-17 | 60 | — | $0 | 7,445 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2025-12-15 | 2025-12-17 | 250 | — | $0 | 14,050 | SEC↗ |
| HULL ANDREW | Director | H Expire deriv | 2025-12-15 | 2025-12-17 | 14 | — | $0 | 961 | SEC↗ |
| Klompas Neil A | Director | A Award deriv | 2025-10-17 | 2025-10-21 | 3,500 | — | $0 | 3,500 | SEC↗ |
| HULL ANDREW | Director | H Expire deriv | 2025-01-11 | 2025-02-03 | 2 | — | $0 | 975 | SEC↗ |
| HULL ANDREW | Director | A Award deriv | 2024-12-20 | 2024-12-23 | 550 | — | $0 | 977 | SEC↗ |
| Baldasare Bryan T | Director | A Award deriv | 2024-12-20 | 2024-12-23 | 550 | — | $0 | 975 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2024-12-20 | 2024-12-23 | 6,250 | — | $0 | 14,300 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2024-12-20 | 2024-12-23 | 2,750 | — | $0 | 5,350 | SEC↗ |
| Grove Janet P | Director | A Award deriv | 2024-12-20 | 2024-12-23 | 550 | — | $0 | 975 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | A Award deriv | 2024-12-20 | 2024-12-23 | 3,750 | — | $0 | 7,505 | SEC↗ |
| Lemerond Nicole | Director | A Award deriv | 2024-12-20 | 2024-12-23 | 550 | — | $0 | 975 | SEC↗ |
| Jagpal Netta | Chief Financial Officer | A Award deriv | 2024-12-20 | 2024-12-23 | 3,750 | — | $0 | 6,250 | SEC↗ |
| Johnson Shane Aaron | Sr VP & General Manager | A Award deriv | 2024-12-20 | 2024-12-23 | 1,500 | — | $0 | 3,900 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Other | S Sale | 2024-07-31 | 2024-08-02 | 240 | $0.18 | $43 | 0 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2024-05-27 | 2024-05-28 | 485 | — | $0 | 52,000 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2024-05-27 | 2024-05-28 | 1,139 | — | $0 | 161,000 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | H Expire deriv | 2024-05-27 | 2024-05-28 | 545 | — | $0 | 52,000 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | H Expire deriv | 2024-05-27 | 2024-05-28 | 394 | — | $0 | 75,100 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | H Expire deriv | 2024-03-04 | 2024-03-05 | 309 | — | $0 | 52,545 | SEC↗ |
| HULL ANDREW | Director | P Buy | 2024-02-21 | 2024-02-22 | 37,500 | $0.39 | $14.6K | 38,258 | SEC↗ |
| ADAMS ERIC A | President & CEO | P Buy | 2024-02-20 | 2024-02-21 | 41,600 | $0.36 | $15.0K | 43,959 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2024-01-21 | 2024-03-05 | 121 | — | $0 | 52,485 | SEC↗ |
| HULL ANDREW | Director | H Expire deriv | 2024-01-14 | 2024-03-05 | 42 | — | $0 | 8,542 | SEC↗ |
| HULL ANDREW | Director | A Award deriv | 2023-12-23 | 2023-12-26 | 7,100 | — | $0 | 8,584 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | A Award deriv | 2023-12-23 | 2023-12-26 | 45,000 | — | $0 | 52,606 | SEC↗ |
| Baldasare Bryan T | Director | A Award deriv | 2023-12-23 | 2023-12-26 | 7,100 | — | $0 | 8,500 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2023-12-23 | 2023-12-26 | 136,000 | — | $0 | 162,139 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2023-12-23 | 2023-12-26 | 45,000 | — | $0 | 52,854 | SEC↗ |
| Grove Janet P | Director | A Award deriv | 2023-12-23 | 2023-12-26 | 7,100 | — | $0 | 8,500 | SEC↗ |
| Tegge Jonathan | Interim CFO | A Award deriv | 2023-12-23 | 2023-12-26 | 30,000 | — | $0 | 31,400 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | A Award deriv | 2023-12-23 | 2023-12-26 | 65,000 | — | $0 | 75,494 | SEC↗ |
| Lemerond Nicole | Director | A Award deriv | 2023-12-23 | 2023-12-26 | 7,100 | — | $0 | 8,500 | SEC↗ |
| Johnson Shane Aaron | Sr VP & General Manager | A Award deriv | 2023-12-23 | 2023-12-26 | 40,000 | — | $0 | 48,000 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | H Expire deriv | 2023-12-05 | 2023-12-06 | 848 | — | $0 | 10,494 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | H Expire deriv | 2023-08-31 | 2023-08-31 | 327 | — | $0 | 7,854 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2023-05-16 | 2023-05-16 | 1,818 | — | $0 | 26,139 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2023-05-16 | 2023-05-16 | 485 | — | $0 | 7,606 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | H Expire deriv | 2023-05-16 | 2023-05-16 | 152 | — | $0 | 8,181 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2023-03-08 | 2023-03-09 | 545 | — | $0 | 27,957 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | H Expire deriv | 2023-03-08 | 2023-03-09 | 545 | — | $0 | 8,333 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2023-03-08 | 2023-03-09 | 61 | — | $0 | 8,091 | SEC↗ |
| HULL ANDREW | Director | A Award deriv | 2022-12-16 | 2022-12-19 | 840 | — | $0 | 1,484 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | A Award deriv | 2022-12-16 | 2022-12-19 | 4,200 | — | $0 | 8,152 | SEC↗ |
| Baldasare Bryan T | Director | A Award deriv | 2022-12-16 | 2022-12-19 | 840 | — | $0 | 1,400 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2022-12-16 | 2022-12-19 | 15,000 | — | $0 | 28,502 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2022-12-16 | 2022-12-19 | 4,200 | — | $0 | 8,878 | SEC↗ |
| Grove Janet P | Director | A Award deriv | 2022-12-16 | 2022-12-19 | 840 | — | $0 | 1,400 | SEC↗ |
| Tegge Jonathan | Interim CFO | A Award deriv | 2022-12-16 | 2022-12-19 | 1,400 | — | $0 | 1,400 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | A Award deriv | 2022-12-16 | 2022-12-19 | 7,500 | — | $0 | 11,342 | SEC↗ |
| Lemerond Nicole | Director | A Award deriv | 2022-12-16 | 2022-12-19 | 840 | — | $0 | 1,400 | SEC↗ |
| Johnson Shane Aaron | Sr VP & General Manager | A Award deriv | 2022-12-16 | 2022-12-19 | 4,200 | — | $0 | 8,000 | SEC↗ |
| Li Sarah | VP Accounting & Controller | A Award deriv | 2022-12-16 | 2022-12-19 | 3,600 | — | $0 | 4,002 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | A Award deriv | 2022-11-14 | 2022-11-15 | 4,200 | — | $0 | 8,152 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2022-11-14 | 2022-11-15 | 15,000 | — | $0 | 28,502 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2022-11-14 | 2022-11-15 | 4,200 | — | $0 | 8,878 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | A Award deriv | 2022-11-14 | 2022-11-15 | 7,500 | — | $0 | 11,342 | SEC↗ |
| Johnson Shane Aaron | Sr. VP & General Manager | A Award deriv | 2022-11-14 | 2022-11-15 | 4,200 | — | $0 | 8,000 | SEC↗ |
| WOUDENBERG MICHAEL | Chief Operating Officer | D To issuer deriv | 2022-11-14 | 2022-11-18 | 7,500 | — | $0 | 3,842 | SEC↗ |
| ADAMS ERIC A | President & CEO | D To issuer deriv | 2022-11-14 | 2022-11-18 | 15,000 | — | $0 | 13,502 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | D To issuer deriv | 2022-11-14 | 2022-11-18 | 4,200 | — | $0 | 4,678 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | D To issuer deriv | 2022-11-14 | 2022-11-18 | 4,200 | — | $0 | 3,952 | SEC↗ |
| Johnson Shane Aaron | Sr VP & General Manager | D To issuer deriv | 2022-11-14 | 2022-11-18 | 4,200 | — | $0 | 3,800 | SEC↗ |
| Lemerond Nicole | Director | A Award deriv | 2022-08-10 | 2022-08-10 | 14,000 | — | $0 | 14,000 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2022-06-02 | 2022-06-02 | 13,636 | — | $0 | 337,576 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2022-06-02 | 2022-06-02 | 1,515 | — | $0 | 98,787 | SEC↗ |
| Baldasare Bryan T | Director | A Award deriv | 2022-05-17 | 2022-05-19 | 14,000 | — | $0 | 14,000 | SEC↗ |
| ADAMS ERIC A | President & CEO | P Buy | 2022-04-14 | 2022-04-18 | 14,160 | $0.89 | $12.6K | 59,003 | SEC↗ |
| ADAMS ERIC A | President & CEO | P Buy | 2022-04-13 | 2022-04-13 | 8,560 | $0.85 | $7.3K | 44,843 | SEC↗ |
| WOUDENBERG MICHAEL | See Remarks | A Award deriv | 2022-02-23 | 2022-02-28 | 5,000 | — | $0 | 96,060 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2022-02-20 | 2022-02-23 | 3,030 | — | $0 | 100,302 | SEC↗ |
| Grove Janet P | Director | A Award deriv | 2022-02-18 | 2022-02-22 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Cutler Adam D. | Director | H Expire deriv | 2022-01-24 | 2022-01-24 | 6,061 | — | $0 | 40,364 | SEC↗ |
| Cutler Adam D. | Director | H Expire deriv | 2022-01-24 | 2022-01-24 | 1,515 | — | $0 | 38,849 | SEC↗ |
| Cutler Adam D. | Director | H Expire deriv | 2022-01-24 | 2022-01-24 | 22,727 | — | $0 | 16,122 | SEC↗ |
| HULL ANDREW | Director | H Expire deriv | 2022-01-24 | 2022-01-24 | 30,303 | — | $0 | 16,122 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | H Expire deriv | 2022-01-24 | 2022-01-24 | 12,121 | — | $0 | 103,332 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2022-01-24 | 2022-01-24 | 60,606 | — | $0 | 351,212 | SEC↗ |
| ADAMS ERIC A | President & CEO | H Expire deriv | 2022-01-24 | 2022-01-24 | 60,606 | — | $0 | 411,818 | SEC↗ |
| Garner William J | Director | H Expire deriv | 2022-01-24 | 2022-01-24 | 24,242 | — | $0 | 16,122 | SEC↗ |
| COLWILL BRUCE | CFO | P Buy | 2022-01-24 | 2022-01-24 | 5,000 | $1.09 | $5.5K | 11,515 | SEC↗ |
| Johnson Shane Aaron | SVP, GM of BayMedica LLC | P Buy | 2022-01-06 | 2022-01-06 | 8,500 | $1.26 | $10.7K | 304,595 | SEC↗ |
| Johnson Shane Aaron | SVP, GM of BayMedica LLC | P Buy | 2021-12-30 | 2021-12-30 | 8,093 | $1.33 | $10.8K | 296,095 | SEC↗ |
| Cutler Adam D. | Director | A Award deriv | 2021-12-29 | 2021-12-30 | 7,000 | — | $0 | 46,425 | SEC↗ |
| Garner William J | Director | A Award deriv | 2021-12-29 | 2021-12-30 | 7,000 | — | $0 | 40,364 | SEC↗ |
| HULL ANDREW | Director | A Award deriv | 2021-12-29 | 2021-12-30 | 7,000 | — | $0 | 46,425 | SEC↗ |
| Sazdanoff Catherine | Director | A Award deriv | 2021-12-29 | 2021-12-30 | 7,000 | — | $0 | 29,091 | SEC↗ |
| Johnson Shane Aaron | SVP, GM of BayMedica LLC | P Buy | 2021-11-15 | 2021-11-15 | 5,000 | $1.37 | $6.9K | 288,002 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | A Award deriv | 2021-10-18 | 2021-10-19 | 35,000 | — | $0 | 115,453 | SEC↗ |
| COLWILL BRUCE | CFO | A Award deriv | 2021-10-18 | 2021-10-19 | 60,000 | — | $0 | 150,303 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2021-10-18 | 2021-10-19 | 125,000 | — | $0 | 472,424 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2021-10-18 | 2021-10-19 | 35,000 | — | $0 | 116,969 | SEC↗ |
| WOUDENBERG MICHAEL | VP, Chem/Manufacturing/Contr | A Award deriv | 2021-10-18 | 2021-10-19 | 30,000 | — | $0 | 91,060 | SEC↗ |
| ADAMS ERIC A | President & CEO | P Buy | 2021-09-29 | 2021-09-30 | 8,800 | $1.73 | $15.2K | 36,283 | SEC↗ |
| COLWILL BRUCE | CFO | P Buy | 2021-09-28 | 2021-09-29 | 5,000 | $1.77 | $8.8K | 6,515 | SEC↗ |
| ADAMS ERIC A | President & CEO | P Buy | 2021-09-28 | 2021-09-29 | 11,400 | $1.75 | $19.9K | 27,483 | SEC↗ |
| ADAMS ERIC A | President & CEO | A Award deriv | 2020-12-16 | 2020-12-18 | 125,000 | — | $0 | 125,000 | SEC↗ |
| COLWILL BRUCE | CFO | A Award deriv | 2020-12-16 | 2020-12-18 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Cutler Adam D. | Director | A Award deriv | 2020-12-16 | 2020-12-18 | 7,000 | — | $0 | 7,000 | SEC↗ |
| Garner William J | Director | A Award deriv | 2020-12-16 | 2020-12-18 | 7,000 | — | $0 | 7,000 | SEC↗ |
| HSU ERIC C | Sr. VP, Pre-Clinical Res/Dev | A Award deriv | 2020-12-16 | 2020-12-18 | 35,000 | — | $0 | 35,000 | SEC↗ |
| HULL ANDREW | Director | A Award deriv | 2020-12-16 | 2020-12-18 | 7,000 | — | $0 | 7,000 | SEC↗ |
| MANCINI ALEXANDRA DIANE JANET | Sr VP, Clinical Reg Affairs | A Award deriv | 2020-12-16 | 2020-12-18 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Sazdanoff Catherine | Director | A Award deriv | 2020-12-16 | 2020-12-18 | 11,000 | — | $0 | 11,000 | SEC↗ |
| Sazdanoff Catherine | Director | A Award deriv | 2020-12-16 | 2020-12-18 | 7,000 | — | $0 | 7,000 | SEC↗ |
| WOUDENBERG MICHAEL | VP, Chem/Manufacturing/Contr | A Award deriv | 2020-12-16 | 2020-12-18 | 30,000 | — | $0 | 30,000 | SEC↗ |